Related Experiment Video
Updated: Aug 15, 2026

A Novel Method for Involving Women of Color at High Risk for Preterm Birth in Research Priority Setting
Published on: January 12, 2018
ALLHAT-LLT: questions, questions, and more questions (and some answers)
Patrick J Skerrett1, Richard C Pasternak
1Harvard Health Publications, Harvard Medical School, 10 Shattuck Street, Suite 612, Boston, MA 02115, USA. pjskerrett@hms.harvard.edu
Insights
The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial--Lipid Lowering Trial (ALLHAT-LLT) found no significant differences in mortality or cardiovascular events between pravastatin and usual care. Small lipid differences limited the ability to confirm statin benefits.
Area of Science:
- Cardiovascular Medicine
- Clinical Trials
- Pharmacology
Background:
- Hypertension and elevated LDL cholesterol are key risk factors for coronary heart disease.
- Statins are widely used to lower LDL cholesterol and reduce cardiovascular events.
- Previous trials suggested significant cardiovascular benefits from LDL cholesterol lowering.
Purpose of the Study:
- To compare the effects of pravastatin versus usual care on cardiovascular outcomes in hypertensive patients.
- To investigate the relationship between LDL cholesterol reduction and cardiovascular event prevention.
Main Methods:
- The ALLHAT-LLT randomized 10,355 participants aged 55+ with hypertension and CHD risk factors.
- Participants received either 40 mg/d pravastatin or usual care for a mean of 4.8 years.
- Outcomes included all-cause mortality, cardiovascular deaths, and a composite of fatal CHD plus nonfatal myocardial infarction.
Main Results:
- A 9.6% difference in total cholesterol and a 16.7% LDL cholesterol difference were observed between arms.
- No significant differences were found in all-cause mortality, cardiovascular deaths, or the composite endpoint.
- The limited lipid differences may explain the null findings regarding cardiovascular benefits.
Conclusions:
- The ALLHAT-LLT results do not contradict previous findings, suggesting LDL cholesterol lowering's importance for statin benefits.
- Greater lipid differences between treatment and control groups may be needed to observe significant clinical impacts.
- The trial highlights challenges in conducting trials amidst evolving understanding of lipid-lowering therapy and gaps in clinical practice.
Abstract:
The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial--Lipid Lowering Trial (ALLHAT-LLT) compared 40 mg/d of pravastatin with usual care among 10,355 men and women aged 55 years or older with stage 1 or 2 hypertension, at least one additional coronary heart disease risk factor, and low-density lipoprotein (LDL) cholesterol levels of 120 to 189 mg/dL. After a mean of 4.8 years of treatment and follow-up, the difference in total cholesterol between the two arms was 9.6%, whereas in a small, nonrandomized subsample, the LDL cholesterol differential was 16.7%. No differences were observed between the pravastatin and usual-care groups with respect to all-cause mortality, cardiovascular deaths, noncardiovascular deaths, and a composite endpoint of fatal coronary heart disease plus nonfatal myocardial infarction. Despite these null findings, the results of ALLHAT-LLT are not inconsistent with previous trials because of the very small lipid differences in the two arms. This indirectly supports the hypothesis that LDL cholesterol lowering is central to the cardiovascular benefits associated with statin therapy, with greater clinical impacts observed when there are greater differences between treatment and control arms. ALLHAT-LLT underscores the difficulty of conducting an open-label trial in an era of rapidly changing professional and public understanding of the possible benefits of lipid-lowering therapy and highlights the substantial gap between actual care in clinical practice and optimal care based on the best knowledge from randomized clinical trials.
More Related Videos
Related Concept Videos
Le Chatelier's Principle: Changing Concentration
Titration Calculations: Weak Acid - Strong Base
For the titration of 25.00 mL of 0.100 M CH3CO2H with 0.100 M NaOH, the reaction can be represented as:
Balancing Redox Equations
High-Performance Liquid Chromatography: Instrumentation
Linear time-invariant Systems
The input-output behavior of an LTI system can be fully defined by its response to an impulsive excitation at its input. Once this impulse response is known, the system's reaction to any other input can be calculated...
Transient and Steady-state Response
These test signals are integral in designing control systems to exhibit two key performance aspects: transient response and steady-state response.

